Document is current
Any future updates will be listed below
-
Authors
Krijgsman, Daniëlle
Schubert, Stephanie A.
Kraaier, Lianne J.
Lu, Yuyan
van Avondt, Kristof
Verdonschot, Meggy E. L.
Leusen, Jeanette H. W.
van den Heuvel, Marius C.
de Kleine, Ruben H.
de Meijer, Vincent E.
Kraal, Kathelijne C. J.
de Krijger, Ronald R.
Zsiros, József
Peng, Weng Chuan
Vercoulen, Yvonne
-
Funding
Funding for this research was provided by:
UMCU, Strategic Program Cancer Boost grant
TKI-Health Holland
- License Information
-
More Information
Article History
Received: 4 May 2025
Accepted: 31 August 2025
First Online: 13 September 2025
Declarations
:
: Yvonne Vercoulen declares a speaker’s fee from Johnson & Johnson, and funding from AlfaSigma and TigaTx B.V. Jeanette Leusen is the scientific founder and shareholder of TigaTx. Weng Chuan Peng and Jeanette Leusen are supported by Oncode Accelerator, a Dutch National Growth Fund project, under grant number NGFOP2201.
